FDA Panel Votes Against Recommending Mepolizumab for COPD FDA Panel Votes Against Recommending Mepolizumab for COPD

An FDA panel recommended against mepolizumab as add-on treatment to inhaled corticosteroid-based maintenance treatment in patients with COPD guided by blood eosinophil counts.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news